<p>Relvar Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD).</p><p>In asthma, it is used for regular treatment of patients from 12 years of age:</p><ul><li>whose symptoms are not controlled with an inhaled corticosteroid and an inhaled short-acting beta-2 agonist;</li><li>whose symptoms are adequately controlled with both inhaled corticosteroids and a long-acting beta-2 agonist.</li></ul><p>In COPD, it is used in adults who have flare-ups of the disease despite regular bronchodilator treatment (treatment to widen the airways).</p><p>Relvar Ellipta contains the active substances fluticasone furoate and vilanterol.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Asthma indication:</p> <p>Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:</p> <ul><li>patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta<sub>2</sub>-agonists.</li> <li>patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.</li> </ul><p>COPD indication:</p> <p>Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.</p></div>
Therapeutic Area (MeSH)
ATC Code
R03AK10
ATC Item
N/A
Pharmacotherapeutic Group
Adrenergics and other drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| fluticasone furoate | N/A | fluticasone furoate |
| vilanterol | N/A | vilanterol |
EMA Name
Relvar Ellipta
Medicine Name
Relvar Ellipta
Aliases
N/ANo risk management plan link.
